$Allakos(ALLK.US)$Allakos | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.8%) SEC announcement · 01/29 17:30
1
1
举报
JCBF楼主 :
Allakos | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-I.R.S. IDENTIFICATION NO. John P. McKearn, Ph.D.(0.2%),I.R.S. IDENTIFICATION NO. Thomas C. Melzer(0.03%)
$Allakos(ALLK.US)$Allakos Announced Topline Data From Its Phase 2 Trial For Lirentelimab In Atopic Dermatitis (ATLAS) And Phase 2B Study In Chronic Spontaneous Urticaria (MAVERICK); The Studies Did Not Meet Their Primary Endpoints
Allakos' 57% reduction in cash burn exhibits resilience, yet it's a high-risk stock due to large cash burn in comparison to market value. Future growth funding may cause substantial share dilution. The firm's ability to secure more funds and its future business growth are key considerations.
Allakos股票讨论区
still think it will be heading back to price gap
SEC announcement
·
01/29 17:30
interesting
Holly S plunged
TIMBER!
Upcoming Ph 2 readouts in Q1 2024…
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$阿里拉姆制药(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...
Current watch ⚡️
👀
暂无评论